NO3134520T3 - - Google Patents
Info
- Publication number
- NO3134520T3 NO3134520T3 NO16722547A NO16722547A NO3134520T3 NO 3134520 T3 NO3134520 T3 NO 3134520T3 NO 16722547 A NO16722547 A NO 16722547A NO 16722547 A NO16722547 A NO 16722547A NO 3134520 T3 NO3134520 T3 NO 3134520T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01038—Beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase (2.4.1.38)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01092—(N-acetylneuraminyl)-galactosylglucosylceramide N-acetylgalactosaminyltransferase (2.4.1.92)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15164864 | 2015-04-23 | ||
| PCT/EP2016/059194 WO2016170186A1 (fr) | 2015-04-23 | 2016-04-25 | Procédé pour la modification d'une glycoprotéine à l'aide d'une glycosyltransférase, une β-(1,4)-n-acétylgalactosaminyltransférase ou une enzyme dérivée de celle-ci |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO3134520T3 true NO3134520T3 (fr) | 2018-05-19 |
Family
ID=52997984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO16722547A NO3134520T3 (fr) | 2015-04-23 | 2016-04-25 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9988661B2 (fr) |
| EP (2) | EP3354726A1 (fr) |
| JP (1) | JP6966162B2 (fr) |
| CN (2) | CN115960981A (fr) |
| DK (1) | DK3134520T3 (fr) |
| ES (1) | ES2659816T3 (fr) |
| HR (1) | HRP20180439T1 (fr) |
| HU (1) | HUE038511T2 (fr) |
| NO (1) | NO3134520T3 (fr) |
| PL (1) | PL3134520T3 (fr) |
| PT (1) | PT3134520T (fr) |
| WO (1) | WO2016170186A1 (fr) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008029281A2 (fr) | 2006-02-10 | 2008-03-13 | Invitrogen Corporation | Marquage et détection de protéines modifiées post-traductionnellement |
| JP2017528124A (ja) | 2014-08-04 | 2017-09-28 | シンアフィックス ビー．ブイ． | ベータ−（１，４）−ｎ−アセチルガラクトサミニルトランスフェラーゼ又はその突然変異体を用いる糖タンパク質の改変方法 |
| EP3413922A1 (fr) | 2016-02-08 | 2018-12-19 | SynAffix B.V. | Lieurs à sulfamide améliorés pour une utilisation dans des bioconjugués |
| WO2017137458A1 (fr) | 2016-02-08 | 2017-08-17 | Synaffix B.V. | Conjugués d'anticorps à indice thérapeutique amélioré pour le ciblage de tumeurs de cd30 et méthode d'amélioration de l'indice thérapeutique de conjugués d'anticorps |
| EP3413920A1 (fr) | 2016-02-08 | 2018-12-19 | Synaffix B.V. | Bioconjugués contenant des séquences de liaison sulfamide pour utilisation à des fins thérapeutiques |
| CN109069658B (zh) | 2016-02-08 | 2022-10-14 | 西纳福克斯股份有限公司 | 用于靶向her2肿瘤的具有改善的治疗指数的抗体-缀合物以及用于改善抗体-缀合物的治疗指数的方法 |
| WO2017137457A1 (fr) | 2016-02-08 | 2017-08-17 | Synaffix B.V. | Conjugués d'anticorps à indice thérapeutique amélioré permettant de cibler des tumeurs positives pour le cd30 et méthode pour améliorer l'indice thérapeutique de conjugués d'anticorps |
| EP3720504A1 (fr) | 2017-12-06 | 2020-10-14 | Synaffix B.V. | Conjugués d'énédiyne |
| US20210402002A1 (en) | 2018-06-19 | 2021-12-30 | Glykos Biomedical Oy | Conjugate |
| JP2021529163A (ja) | 2018-06-29 | 2021-10-28 | グリコス バイオメディカル オーワイ | コンジュゲート |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US20210308273A1 (en) | 2018-08-02 | 2021-10-07 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| KR20210081324A (ko) | 2018-08-02 | 2021-07-01 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도 |
| EP3876998A1 (fr) | 2018-11-05 | 2021-09-15 | Synaffix B.V. | Anticorps-conjugués pour le ciblage de tumeurs exprimant trop -2 |
| GB201901608D0 (en) | 2019-02-06 | 2019-03-27 | Vib Vzw | Vaccine adjuvant conjugates |
| CN110195043A (zh) * | 2019-05-15 | 2019-09-03 | 武汉格莱利生物科技有限公司 | 一种高水溶性的cgta酶及其制备方法和应用 |
| WO2020245229A1 (fr) | 2019-06-03 | 2020-12-10 | Synaffix B.V. | Lieurs clivables à base d'acétal |
| NL2023572B1 (en) | 2019-07-25 | 2021-02-10 | Synaffix Bv | Synthesis of 6-azido-6-deoxy-2-N-acetyl-hexosamine-nucleoside diphosphate |
| US20230038373A1 (en) | 2019-12-18 | 2023-02-09 | Glykos Biomedical Oy | Stabile conjugate |
| US11786605B2 (en) | 2020-01-09 | 2023-10-17 | Mersana Therapeutics, Inc. | Site specific antibody-drug conjugates with peptide-containing linkers |
| WO2021144314A1 (fr) | 2020-01-13 | 2021-07-22 | Synaffix B.V. | Anticorps fonctionnalisés bilatéralement par cycloaddition |
| EP4090377A1 (fr) | 2020-01-13 | 2022-11-23 | Synaffix B.V. | Conjugués d'anticorps et d'agents de mise en contact de cellules immunitaires |
| CN115666656A (zh) | 2020-01-13 | 2023-01-31 | 西纳福克斯股份有限公司 | 通过环加成双侧功能化抗体 |
| NL2026400B1 (en) | 2020-09-02 | 2022-05-04 | Synaffix Bv | Methods for the preparation of bioconjugates |
| EP4213885A1 (fr) | 2020-09-15 | 2023-07-26 | Synaffix B.V. | Conjugués anticorps-exatecan |
| NL2026947B1 (en) | 2020-11-20 | 2022-07-01 | Synaffix Bv | Tyrosine-based antibody conjugates |
| WO2022136705A1 (fr) | 2020-12-24 | 2022-06-30 | Synaffix B.V. | Anticorps conjugués au glycane se liant au récepteur fc-gamma |
| MX2023008000A (es) | 2021-01-04 | 2023-07-13 | Mersana Therapeutics Inc | Conjugados de anticuerpo dirigido a b7-h4 y farmaco, y metodos de uso de los mismos. |
| WO2022167689A1 (fr) | 2021-02-08 | 2022-08-11 | Synaffix B.V. | Anticorps multifonctionnels |
| JP2024512324A (ja) | 2021-03-05 | 2024-03-19 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｃｄ４４抗体およびその使用 |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| CA3228178A1 (fr) | 2021-08-05 | 2023-02-09 | Go Therapeutics, Inc. | Anticorps anti-glyco-muc4 et leurs utilisations |
| WO2023161296A1 (fr) | 2022-02-22 | 2023-08-31 | Adc Therapeutics Sa | Procédé de conjugaison impliquant une transglutaminase au niveau de la région fc comprenant un n-glycane tronqué |
| WO2023180490A1 (fr) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Conjugués d'anticorps pour le ciblage de tumeurs exprimant nectine-4 |
| WO2023180489A1 (fr) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Anticorps-conjugués pour le ciblage de tumeurs exprimant un antigène carcinoembryonnaire |
| WO2023180485A1 (fr) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Anticorps-conjugués pour le ciblage de tumeurs exprimant trop-2 |
| WO2023180484A1 (fr) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Conjugués d'anticorps pour le ciblage de tumeurs exprimant ptk7 |
| US11931421B2 (en) | 2022-04-15 | 2024-03-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
| EP4285934A1 (fr) | 2022-05-30 | 2023-12-06 | CER Groupe | Trimannose-oligosaccharides modifiés, n-glycanes à deux bras comprenant de tels lesdits coeurs de trimannose et procédé pour les obtenir |
| WO2024038065A1 (fr) | 2022-08-15 | 2024-02-22 | Synaffix B.V. | Anthracyclines et leurs conjugués |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1357182A1 (fr) * | 2000-12-21 | 2003-10-29 | Kyowa Hakko Kogyo Co., Ltd | Proc d de production d'udp-n-ac tylgalactosamine et de saccharide contenant une n-ac tylgalactosamine |
| FI20011671A (fi) | 2001-08-20 | 2003-02-21 | Carbion Oy | Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö |
| AU2003270645A1 (en) * | 2002-09-13 | 2004-04-30 | Richard D. Cummings | Beta1,4-N-ACETYLGALACTOSAMINYLTRANSFERASES, NUCLEIC ACIDS AND METHODS OF USE THEREOF |
| EP1797192A1 (fr) | 2004-09-29 | 2007-06-20 | Novo Nordisk Health Care AG | Proteines modifiees |
| WO2008029281A2 (fr) | 2006-02-10 | 2008-03-13 | Invitrogen Corporation | Marquage et détection de protéines modifiées post-traductionnellement |
| UY32621A (es) * | 2009-05-11 | 2010-12-31 | Stichting Tech Wetenschapp | Antígeno glicano |
| CN101575631B (zh) * | 2009-05-15 | 2011-11-16 | 南开大学 | 一种半乳糖基转移酶修饰黄酮类糖苷化合物的方法 |
| CN102313801A (zh) * | 2011-06-03 | 2012-01-11 | 南开大学 | 一种抗体的代谢标记方法及其荧光检测中的应用 |
| GB201115841D0 (en) | 2011-09-13 | 2011-10-26 | Genovis Ab | Protein and method |
| CN110201186A (zh) * | 2012-10-23 | 2019-09-06 | 西纳福克斯股份有限公司 | 经修饰的抗体、抗体-缀合物及其制备方法 |
| WO2015112016A1 (fr) | 2014-01-24 | 2015-07-30 | Synaffix B.V. | Procédé de cycloaddition d'un composé 1,3-dippole halogéné avec un (hétéro)cycloalkyne |
| EP3733209A1 (fr) | 2014-10-03 | 2020-11-04 | Synaffix B.V. | Liaison de sulfamide, leurs conjugués et procédés de préparation |
-
2016
- 2016-04-25 JP JP2017548981A patent/JP6966162B2/ja active Active
- 2016-04-25 CN CN202211121609.5A patent/CN115960981A/zh active Pending
- 2016-04-25 WO PCT/EP2016/059194 patent/WO2016170186A1/fr active Application Filing
- 2016-04-25 PL PL16722547T patent/PL3134520T3/pl unknown
- 2016-04-25 PT PT167225473T patent/PT3134520T/pt unknown
- 2016-04-25 NO NO16722547A patent/NO3134520T3/no unknown
- 2016-04-25 EP EP17208517.7A patent/EP3354726A1/fr active Pending
- 2016-04-25 EP EP16722547.3A patent/EP3134520B1/fr active Active
- 2016-04-25 CN CN201680036546.XA patent/CN107810273B/zh active Active
- 2016-04-25 US US15/318,248 patent/US9988661B2/en active Active
- 2016-04-25 HU HUE16722547A patent/HUE038511T2/hu unknown
- 2016-04-25 ES ES16722547.3T patent/ES2659816T3/es active Active
- 2016-04-25 DK DK16722547.3T patent/DK3134520T3/en active
-
2018
- 2018-03-14 HR HRP20180439TT patent/HRP20180439T1/hr unknown
- 2018-05-04 US US15/971,233 patent/US11299759B2/en active Active
-
2022
- 2022-04-01 US US17/711,423 patent/US20230100074A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230100074A1 (en) | 2023-03-30 |
| US11299759B2 (en) | 2022-04-12 |
| JP2018518149A (ja) | 2018-07-12 |
| CN107810273B (zh) | 2022-09-27 |
| WO2016170186A1 (fr) | 2016-10-27 |
| EP3134520A1 (fr) | 2017-03-01 |
| US9988661B2 (en) | 2018-06-05 |
| EP3134520B1 (fr) | 2017-12-20 |
| JP6966162B2 (ja) | 2021-11-10 |
| US20170130256A1 (en) | 2017-05-11 |
| HRP20180439T1 (hr) | 2018-07-13 |
| CN107810273A (zh) | 2018-03-16 |
| PT3134520T (pt) | 2018-03-26 |
| CN115960981A (zh) | 2023-04-14 |
| DK3134520T3 (en) | 2018-03-19 |
| EP3354726A1 (fr) | 2018-08-01 |
| PL3134520T3 (pl) | 2018-06-29 |
| US20180245119A1 (en) | 2018-08-30 |
| HUE038511T2 (hu) | 2018-10-29 |
| ES2659816T3 (es) | 2018-03-19 |